Biolumpivaxin : New vaccine launched in India against lumpy skin disease in the cattle
Biovet, a subsidiary of Bharat Biotech, has launched Biolumpivaxin, a vaccine developed to combat lumpy skin disease (LSD) in dairy cattle and buffaloes, as per reports. The vaccine was introduced during the Livestock Prosperity Conclave in Vijayawada on May 14, 2025.LSD, caused by a virus from the Capripoxvirus genus, leads to nodules on the skin, fever, and reduced milk production in affected animals. Biolumpivaxin is reportedly the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, enabling differentiation between vaccinated and naturally infected cattle.It is a live-attenuated vaccine developed using the LSD virus/Ranchi/2019 strain, in collaboration with the Indian Council of Agricultural Research-National Research Centre on Equines (ICAR-NRCE), as per reports. The vaccine is administered once a year and is available in multi-dose vials ranging from 25 to 100 doses, stable at 2-8°C. Biovet's production facilities in Bengaluru can reportedly produce up to 500 million doses annually, ensuring sustainable supply. India experienced significant LSD outbreaks in 2019 and 2022, resulting in the death of approximately 2,00,000 cattle and substantial economic losses. The introduction of Biolumpivaxin aims to bolster livestock health and support the dairy industry's sustainability.
Biovet, a subsidiary of Bharat Biotech, has launched Biolumpivaxin, a vaccine developed to combat lumpy skin disease (LSD) in dairy cattle and buffaloes, as per reports. The vaccine was introduced during the Livestock Prosperity Conclave in Vijayawada on May 14, 2025.
LSD, caused by a virus from the Capripoxvirus genus, leads to nodules on the skin, fever, and reduced milk production in affected animals. Biolumpivaxin is reportedly the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, enabling differentiation between vaccinated and naturally infected cattle.
It is a live-attenuated vaccine developed using the LSD virus/Ranchi/2019 strain, in collaboration with the Indian Council of Agricultural Research-National Research Centre on Equines (ICAR-NRCE), as per reports.
The vaccine is administered once a year and is available in multi-dose vials ranging from 25 to 100 doses, stable at 2-8°C. Biovet's production facilities in Bengaluru can reportedly produce up to 500 million doses annually, ensuring sustainable supply.
India experienced significant LSD outbreaks in 2019 and 2022, resulting in the death of approximately 2,00,000 cattle and substantial economic losses. The introduction of Biolumpivaxin aims to bolster livestock health and support the dairy industry's sustainability.
What's Your Reaction?
